Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Gradishar WJ, Moran MS, Abraham J, Aft R, Agneese D, Allison KH, Anderson BO et al (2021) Breast Cancer NCCN Guidelines Version 1.2021. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 23 Jan 2021
2. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu M-C, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay M-A, Riva A, Crown J (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283. https://doi.org/10.1056/NEJMoa0910383
3. Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. https://doi.org/10.1186/1471-2407-11-404
4. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266. https://doi.org/10.1002/cncr.21847
5. Wildiers H, Reiser M (2011) Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 77(3):221–240. https://doi.org/10.1016/j.critrevonc.2010.02.002